NRG-103
AXP000060.1 · Oncolytic virus
- Platform
- adenovirus
- Sponsor
- Zhongnan Hospital of Wuhan University
Names
| Name | Type | Source |
|---|---|---|
| NRG-103 | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus (serotype not reported)
- Replication
- conditionally replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07710690 | A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma | Recruiting | Phase 1 | 2026-07-09 | 2030-04-30 | 24 | HGG; High Grade Glioma; High Grade Glioma (III or IV) |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | Recruiting | Early phase 1 | 2024-12-19 | 2027-08 | 15 | Glioblastoma (GBM) |
Recent changes
No changes recorded in its trials yet.
Notes
Oncolytic adenovirus in an early-phase trial at Zhongnan Hospital (NCT06757153). Construct, transgenes and originator not found; entered on the strength of the trial registration alone.
How to cite
NRG-103 (AXP000060.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000060.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.